Improving Informed Consent for Palliative Chemotherapy

NACompletedINTERVENTIONAL
Enrollment

216

Participants

Timeline

Start Date

June 10, 2015

Primary Completion Date

September 27, 2017

Study Completion Date

September 27, 2017

Conditions
Metastatic Colorectal CancerMetastatic Pancreatic CancerUnresectable Pancreatic Cancer
Interventions
OTHER

Investigational informed consent for chemotherapy

Investigational informed consent materials consist of regimen-specific multimedia tools: a video plus a booklet.

OTHER

Usual, standard-of-care informed consent for chemotherapy

The enrolling site's institutional standard-of-care informed consent materials.

Trial Locations (8)

23284

Virginia Commonwealth University, Richmond

27103

Novant Health, Winston-Salem

27599

University of North Carolina at Chapel Hill, Chapel Hill

94143

University of California at San Francisco, San Francisco

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

01757

Dana-Farber at Milford, Milford

02190

Dana-Farber at South Shore, South Weymouth

All Listed Sponsors
collaborator

Patient-Centered Outcomes Research Institute

OTHER

collaborator

Alliance for Clinical Trials in Oncology

OTHER

collaborator

National Cancer Institute (NCI)

NIH

lead

Dana-Farber Cancer Institute

OTHER

NCT02282722 - Improving Informed Consent for Palliative Chemotherapy | Biotech Hunter | Biotech Hunter